J&J has been hunting for companies to buy. At the start of the year, the company’s new CEO Joaquin Duato said J&J would take a more “aggressive” approach to dealmaking, although he and other executives had indicated a preference toward small- and mid-sized acquisitions of medical technology and biotechnology companies.
Analysts had previously speculated that J&J could acquire a cardiology firm such as Boston Scientific.
In a statement, Duato said in the acquisition of Abiomed is “an important step in the execution of our strategic priorities” as the company focuses on its pharma and medtech businesses.
“We have committed to enhancing our position in medtech by entering high-growth segments,” he added. “The addition of Abiomed provides a strategic platform to advance breakthrough treatments in cardiovascular disease and helps more patients around the world while driving value for our shareholders.” READ MORE
by Elise Reuter
Source: biopharmadive.com
The biotech has entered into a licensing and collaboration agreement with Swedish company AlzeCure Pharma for rights to the latter’s Alzheimer’s platform NeuroRestore, including the leading drug candidate ACD856. QuantumCell is paying only $12m upfront, but a tail-heavy weighting to the deal with milestone payments means the total transaction could exceed $2.2bn.
Under a new five-year agreement, Haleon plans wider adoption of AI-powered tools to help employees “automate routine tasks, collaborate more effectively and focus on higher-value work,” the London-based company said in a July 1 announcement days after Microsoft revealed the deal. The Advil maker already used Microsoft 365 Copilot before the latest relationship upgrade.
With over 25 years of experience in the international CDMO and biotechnology industries, Torsten Woehr combines strong leadership skills in the commercial sector with in-depth knowledge of operational business. Most recently, he served as Chief Commercial Officer of Bachem, where he led global business operations and drove key strategic investments.
